WO2020179712A1 - Procédés de prédiction de la réponse tumorale à l'éribuline - Google Patents
Procédés de prédiction de la réponse tumorale à l'éribuline Download PDFInfo
- Publication number
- WO2020179712A1 WO2020179712A1 PCT/JP2020/008485 JP2020008485W WO2020179712A1 WO 2020179712 A1 WO2020179712 A1 WO 2020179712A1 JP 2020008485 W JP2020008485 W JP 2020008485W WO 2020179712 A1 WO2020179712 A1 WO 2020179712A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- eribulin
- expression
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention concerne des procédés, des compositions et des kits pour déterminer des approches pour le traitement du cancer, ainsi que des méthodes de traitement du cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962812836P | 2019-03-01 | 2019-03-01 | |
US62/812,836 | 2019-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020179712A1 true WO2020179712A1 (fr) | 2020-09-10 |
Family
ID=72338722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/008485 WO2020179712A1 (fr) | 2019-03-01 | 2020-02-28 | Procédés de prédiction de la réponse tumorale à l'éribuline |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020179712A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113512733A (zh) * | 2021-05-13 | 2021-10-19 | 浙江工业大学 | 一种电化学nhk反应合成艾日布林中间体的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014509515A (ja) * | 2011-03-18 | 2014-04-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | エリブリンに対する応答を予測するための方法及び組成物 |
-
2020
- 2020-02-28 WO PCT/JP2020/008485 patent/WO2020179712A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014509515A (ja) * | 2011-03-18 | 2014-04-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | エリブリンに対する応答を予測するための方法及び組成物 |
Non-Patent Citations (2)
Title |
---|
COOMBES R C; ARMSTRONG A; AHMED S; PAGE K; HASTINGS R K; SALARI R; SETHI H; BOYDELL A R; SHCHEGROVA S V; FERNANDEZ-GARCIA D; GLEAS: "Abstract P4-01-02: Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumour DNA (ctDNA) antedates overt metastatic recurrence", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 79, no. 4, Supplement 1, Abstract P4-01-02, 1 February 2019 (2019-02-01), US, XP009514404, ISSN: 1538-7445, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/79/4_Supplement/P4-01-02> DOI: 10.1158/1538-7445.SABCS18-P4-01-02 * |
KAUL ROMA; RISINGER APRIL L.; MOOBERRY SUSAN L.: "Eribulin rapidly inhibits TGF-β-induced Snail expression and can induce Slug expression in a Smad4-dependent manner", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 121, no. 7, 4 September 2019 (2019-09-04), GB, pages 611 - 621, XP036895370, ISSN: 0007-0920, DOI: 10.1038/s41416-019-0556-9 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113512733A (zh) * | 2021-05-13 | 2021-10-19 | 浙江工业大学 | 一种电化学nhk反应合成艾日布林中间体的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nelson et al. | Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity | |
JP2019150027A5 (fr) | ||
Galletti et al. | Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device | |
Wang et al. | Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in lung cancer | |
US10345309B2 (en) | Biomarkers for gastric cancer and uses thereof | |
JP2014509515A5 (fr) | ||
Miyamoto et al. | Significance of progesterone receptor-A and-B expressions in endometrial adenocarcinoma | |
RU2008136193A (ru) | Детектирование рака по повышенным уровням bcl-2 | |
JP2015517801A5 (fr) | ||
Kim et al. | Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients | |
Gorka et al. | NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas | |
Lankiewicz et al. | Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment | |
Liu et al. | Increased levels of SLP-2 correlate with poor prognosis in gastric cancer | |
Portier et al. | HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma | |
KR20110065512A (ko) | 암의 진단 방법 및 암 환자의 전반적 생존 및 무질병 생존의 측정 방법 | |
Zhao et al. | Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma | |
Chen et al. | GP73 is down-regulated in gastric cancer and associated with tumor differentiation | |
JP2022153460A (ja) | 膀胱がんのバイオマーカーとしてのケラチン17 | |
WO2020179712A1 (fr) | Procédés de prédiction de la réponse tumorale à l'éribuline | |
Makhlouf et al. | The clinical and biological significance of estrogen receptor-low positive breast cancer | |
Shi et al. | Correlation between HER-2 gene amplification or protein expression and clinical pathological features of breast cancer | |
Lim et al. | Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor | |
WO2013112528A1 (fr) | Méthodes et compositions se rapportant aux troubles prolifératifs de la prostate | |
CA3112792A1 (fr) | Methode de selection pour le traitement d'individus presentant un risque de cancer du sein invasif | |
WO2012010105A1 (fr) | Procédés pour la détection de système létal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20766622 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20766622 Country of ref document: EP Kind code of ref document: A1 |